[go: up one dir, main page]

WO2018231176A3 - Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation - Google Patents

Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation Download PDF

Info

Publication number
WO2018231176A3
WO2018231176A3 PCT/TR2017/050637 TR2017050637W WO2018231176A3 WO 2018231176 A3 WO2018231176 A3 WO 2018231176A3 TR 2017050637 W TR2017050637 W TR 2017050637W WO 2018231176 A3 WO2018231176 A3 WO 2018231176A3
Authority
WO
WIPO (PCT)
Prior art keywords
diclofenac
inflammation
pain
combinations
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2017/050637
Other languages
French (fr)
Other versions
WO2018231176A2 (en
WO2018231176A9 (en
Inventor
Mehmet Nevzat PISAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2016/18037A external-priority patent/TR201618037A2/en
Application filed by Individual filed Critical Individual
Priority to EA201991384A priority Critical patent/EA201991384A1/en
Priority to US16/465,862 priority patent/US20190307713A1/en
Publication of WO2018231176A2 publication Critical patent/WO2018231176A2/en
Publication of WO2018231176A3 publication Critical patent/WO2018231176A3/en
Publication of WO2018231176A9 publication Critical patent/WO2018231176A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A single unit pharmaceutical dosage form comprising: diclofenac or a pharmaceutically acceptable salt thereof; and an H2 receptor antagonist, preferably famotidine or a pharmaceutically acceptable salt thereof, wherein diclofenac has a Tmax of between about and 50 minutes after administering said formulation to a patient.
PCT/TR2017/050637 2016-12-07 2017-12-07 Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation Ceased WO2018231176A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201991384A EA201991384A1 (en) 2016-12-07 2017-12-07 COMBINATIONS OF DICLOFENAC AND H2-RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN AND INFLAMMATION
US16/465,862 US20190307713A1 (en) 2016-12-07 2017-12-07 Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
TR2016/18037 2016-12-07
TR2016/18037A TR201618037A2 (en) 2016-12-07 2016-12-07 DICLOFENAC AND H2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN AND INFLAMMATION
TR2017/11764 2017-08-09
TR2017/11764A TR201711764A2 (en) 2016-12-07 2017-08-09 Diclofenac and h2 receptor antagonists for treatment of pain and inflammation
TR2017/17134A TR201717134A2 (en) 2016-12-07 2017-11-02 Rapid Release Oral Combinations of Diclofenac and H2 Receptor Antagonists for Rapid Treatment of Pain and Inflammation
TR2017/17134 2017-11-02

Publications (3)

Publication Number Publication Date
WO2018231176A2 WO2018231176A2 (en) 2018-12-20
WO2018231176A3 true WO2018231176A3 (en) 2019-02-21
WO2018231176A9 WO2018231176A9 (en) 2019-04-04

Family

ID=64605656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050637 Ceased WO2018231176A2 (en) 2016-12-07 2017-12-07 Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation

Country Status (2)

Country Link
TR (1) TR201717134A2 (en)
WO (1) WO2018231176A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
WO2008004231A1 (en) * 2006-07-07 2008-01-10 Tiltan Pharma Ltd. Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
WO2012144964A1 (en) * 2011-04-18 2012-10-26 Ak Kimya Ithalat-Lhracat Ve Sanayii A.S. Thiocolchicoside, diclofenac and lansoprazole combinations
WO2013111070A1 (en) * 2012-01-23 2013-08-01 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
US20150290174A1 (en) * 2014-04-11 2015-10-15 Resuscitate MOE LLC Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159129A0 (en) 2001-06-01 2004-05-12 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
US20050163847A1 (en) 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US20090233970A1 (en) 2008-03-11 2009-09-17 Nickell Robert P Combined nsaid and acid blocker formulation and method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
WO2008004231A1 (en) * 2006-07-07 2008-01-10 Tiltan Pharma Ltd. Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
WO2012144964A1 (en) * 2011-04-18 2012-10-26 Ak Kimya Ithalat-Lhracat Ve Sanayii A.S. Thiocolchicoside, diclofenac and lansoprazole combinations
WO2013111070A1 (en) * 2012-01-23 2013-08-01 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
US20150290174A1 (en) * 2014-04-11 2015-10-15 Resuscitate MOE LLC Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAPLE D R ET AL: "Development of stabilating indicating analytical method for famotidine and diclofenac potasium in combined dosage form", INDIAN DRUGS, vol. 49, no. 6, 31 May 2012 (2012-05-31), pages 40 - 42, XP009510566, ISSN: 0019-462X, Retrieved from the Internet <URL:http://www.indiandrugsonline.org/issuesarticle-details?id=MjI3> [retrieved on 20190118] *
SURYAKUMAR J ET AL: "FAMOTIDINE AFFECTS THE PHARMACOKINETICS OF DICLOFENAC SODIUM", DRUG INVESTIGAT, ADIS INTERNATIONAL, NZ, vol. 4, no. 1, 1 January 1992 (1992-01-01), pages 66 - 68, XP008031074, ISSN: 0114-2402 *

Also Published As

Publication number Publication date
WO2018231176A2 (en) 2018-12-20
TR201717134A2 (en) 2018-07-23
WO2018231176A9 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
HRP20200600T1 (en) Tapentadol for preventing and treating depression and anxiety
WO2011157416A3 (en) Transdermal administration of memantine
HK1221646A1 (en) Use of high dose pridopidine for treating huntington&#39;s disease
IL314347A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
JP2016501828A5 (en)
JP2015523407A5 (en)
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
NZ605469A (en) Nalbuphine-based formulations and uses thereof
BR112013010829B8 (en) Intravenous pharmaceutical composition to provide relief from pain and/or inflammation
MY206893A (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
EP4410295A3 (en) Use of vibegron to treat overactive bladder
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
HK1255584A1 (en) Combination therapy using acamprosate and d-cycloserine
JP2016505050A5 (en)
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
Sturn et al. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients
HRP20211661T1 (en) IGMEZIN, INTENDED FOR USE IN THE TREATMENT OF ALZHEIMER&#39;S DISEASE
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
WO2018231176A3 (en) Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation
JP2015516451A5 (en)
HK1198580A1 (en) Novel therapeutic use of p75 receptor antagonists
WO2019203759A3 (en) Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation.
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 19/07/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17909666

Country of ref document: EP

Kind code of ref document: A2